$ANNA
AleAnna, Inc.

2022 Q4 Form 10-K Financial Statement

#000119312523110542 Filed on April 21, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $452.4K $1.453M
YoY Change 240.8% 941.5%
Operating Profit -$1.453M
YoY Change
Interest Expense $1.609M $2.542M
YoY Change 335070.83% 529585.42%
% of Operating Profit
Other Income/Expense, Net $0.00 -$30.00K
YoY Change -100.0% -91.28%
Pretax Income $1.156M $1.060M
YoY Change -342.81% -319.42%
Income Tax
% Of Pretax Income
Net Earnings $1.156M $1.060M
YoY Change -342.81% -319.42%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.04 $0.04
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $461.9K $461.9K
YoY Change -47.27% -47.27%
Cash & Equivalents $461.9K
Short-Term Investments
Other Short-Term Assets $514.2K $514.2K
YoY Change -52.39% -52.39%
Inventory
Prepaid Expenses $514.2K
Receivables
Other Receivables
Total Short-Term Assets $976.1K $976.1K
YoY Change -32.08% -49.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $229.8M $229.8M
YoY Change 13.76% 13.76%
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $229.8M $229.8M
YoY Change 13.47% 13.76%
TOTAL ASSETS
Total Short-Term Assets $976.1K $976.1K
Total Long-Term Assets $229.8M $229.8M
Total Assets $230.8M $230.8M
YoY Change 13.15% 13.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $51.45K $51.45K
YoY Change 55.65% 55.91%
Accrued Expenses $504.2K $859.1K
YoY Change 531.21% 973.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $912.9K $912.9K
YoY Change 109.66% 109.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.875M $7.875M
YoY Change -96.23% -96.23%
Total Long-Term Liabilities $7.875M $7.875M
YoY Change -96.23% -96.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $912.9K $912.9K
Total Long-Term Liabilities $7.875M $7.875M
Total Liabilities $8.788M $8.788M
YoY Change 18.19% -95.8%
SHAREHOLDERS EQUITY
Retained Earnings -$7.712M
YoY Change 40.62%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.712M $222.0M
YoY Change
Total Liabilities & Shareholders Equity $230.8M $230.8M
YoY Change 13.15% 13.15%

Cashflow Statement

Concept 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $1.156M $1.060M
YoY Change -342.81% -319.42%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$69.16K -$413.9K
YoY Change -93.71% -62.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$25.25M
YoY Change -100.0% -94.02%
Cash From Investing Activities $0.00 -$25.25M
YoY Change -100.0% -87.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 25.25M
YoY Change -100.0% -87.62%
NET CHANGE
Cash From Operating Activities -69.16K -413.9K
Cash From Investing Activities 0.000 -25.25M
Cash From Financing Activities 0.000 25.25M
Net Change In Cash -69.16K -413.9K
YoY Change -107.9% -147.04%
FREE CASH FLOW
Cash From Operating Activities -$69.16K -$413.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001845123
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity Registrant Name
EntityRegistrantName
Swiftmerge Acquisition Corp.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2022 dei Entity File Number
EntityFileNumber
001-41164
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1582153
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
4318 Forman Ave
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Toluca Lake
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91602
CY2022 dei City Area Code
CityAreaCode
424
CY2022 dei Local Phone Number
LocalPhoneNumber
431-0030
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2022Q2 dei Entity Public Float
EntityPublicFloat
220950000
CY2022 ivcp Period To Redeem Public Shares If Business Combination Is Not Completed Within Initial Combination Period
PeriodToRedeemPublicSharesIfBusinessCombinationIsNotCompletedWithinInitialCombinationPeriod
P10D
CY2022 dei Auditor Firm
AuditorFirmId
688
CY2022 dei Auditor Name
AuditorName
Marcum LLP
CY2022 dei Auditor Location
AuditorLocation
Boston, MA
CY2022Q4 us-gaap Cash
Cash
461914
CY2021Q4 us-gaap Cash
Cash
875831
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
514200
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
561405
CY2022Q4 us-gaap Assets Current
AssetsCurrent
976114
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1437236
CY2022Q4 ivcp Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
0
CY2021Q4 ivcp Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
513628
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
229792494
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
202000481
CY2022Q4 us-gaap Assets
Assets
230768608
CY2021Q4 us-gaap Assets
Assets
203951345
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
51453
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
33057
CY2022Q4 ivcp Accrued Offering Costs Current
AccruedOfferingCostsCurrent
-311430
CY2021Q4 ivcp Accrued Offering Costs Current
AccruedOfferingCostsCurrent
-320185
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2284
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2284
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
504181
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
75359
CY2022Q4 ivcp Accrued Expenses Related Party
AccruedExpensesRelatedParty
43516
CY2021Q4 ivcp Accrued Expenses Related Party
AccruedExpensesRelatedParty
4516
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
912864
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
435401
CY2022Q4 ivcp Deferred Underwriting Fee Payable Non Current
DeferredUnderwritingFeePayableNonCurrent
7875000
CY2021Q4 ivcp Deferred Underwriting Fee Payable Non Current
DeferredUnderwritingFeePayableNonCurrent
7000000
CY2022Q4 us-gaap Liabilities
Liabilities
8787864
CY2021Q4 us-gaap Liabilities
Liabilities
7435401
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
22500000
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
22500000
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
20000000
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
20000000
CY2022Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.21
CY2021Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.1
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
229692494
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
202000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7712312
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5484631
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-7711750
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5484056
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
230768608
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203951345
CY2022 ivcp Formation And Operating Costs
FormationAndOperatingCosts
1452694
ivcp Formation And Operating Costs
FormationAndOperatingCosts
139479
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-1452694
us-gaap Operating Income Loss
OperatingIncomeLoss
-139479
CY2022 ivcp Loss On Sale Of Private Placement Warrants
LossOnSaleOfPrivatePlacementWarrants
30000
ivcp Loss On Sale Of Private Placement Warrants
LossOnSaleOfPrivatePlacementWarrants
343999
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
2542494
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
311
CY2022 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
170
CY2022 us-gaap Net Income Loss
NetIncomeLoss
1059800
us-gaap Net Income Loss
NetIncomeLoss
-482997
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5484056
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1181250
CY2022 ivcp Proceeds From Sale Of Private Placement Warrants Net Of Offering Costs
ProceedsFromSaleOfPrivatePlacementWarrantsNetOfOfferingCosts
780000
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2442494
CY2022 ivcp Adjustment To Additional Paid In Capital Accretion Of Class A Ordinary Shares From Issuance Of Overallotment Warrants
AdjustmentToAdditionalPaidInCapitalAccretionOfClassAOrdinarySharesFromIssuanceOfOverallotmentWarrants
2806250
CY2022 us-gaap Net Income Loss
NetIncomeLoss
1059800
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-7711750
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
0
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
9975271
ivcp Proceeds From Sale Of Private Placement Warrants Net Of Offering Costs
ProceedsFromSaleOfPrivatePlacementWarrantsNetOfOfferingCosts
8343151
CY2022 ivcp Excess Fair Value Of Founder Shares Attributable To Anchor Investors
ExcessFairValueOfFounderSharesAttributableToAnchorInvestors
0
ivcp Excess Fair Value Of Founder Shares Attributable To Anchor Investors
ExcessFairValueOfFounderSharesAttributableToAnchorInvestors
13605750
ivcp Purchase Of Shares By Anchor Investors Including Excess Fair Value Over Purchase Price Value
PurchaseOfSharesByAnchorInvestorsIncludingExcessFairValueOverPurchasePriceValue
13613657
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
36958138
us-gaap Net Income Loss
NetIncomeLoss
-482997
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5484056
CY2022 us-gaap Net Income Loss
NetIncomeLoss
1059800
us-gaap Net Income Loss
NetIncomeLoss
-482997
CY2022 ivcp Loss On Sale Of Private Placement Warrants
LossOnSaleOfPrivatePlacementWarrants
30000
ivcp Loss On Sale Of Private Placement Warrants
LossOnSaleOfPrivatePlacementWarrants
343999
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
2542494
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
311
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
170
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-560833
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1075033
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
18394
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
33057
CY2022 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
2284
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
429305
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
79875
CY2022 ivcp Accrued Offering Costs
AccruedOfferingCosts
-8755
ivcp Accrued Offering Costs
AccruedOfferingCosts
0
CY2022 ivcp Increase Decrease In Accrued Liabilities Related Party
IncreaseDecreaseInAccruedLiabilitiesRelatedParty
39000
ivcp Increase Decrease In Accrued Liabilities Related Party
IncreaseDecreaseInAccruedLiabilitiesRelatedParty
0
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-413917
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1099296
CY2022 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
25250000
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
202000000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25250000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-202000000
CY2022 ivcp Proceeds From Issuance Initial Public Offering Net Of Underwriting Discount
ProceedsFromIssuanceInitialPublicOfferingNetOfUnderwritingDiscount
24500000
ivcp Proceeds From Issuance Initial Public Offering Net Of Underwriting Discount
ProceedsFromIssuanceInitialPublicOfferingNetOfUnderwritingDiscount
196000000
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
750000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8600000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000
CY2022 ivcp Proceeds From Issuance Of Ordinary Shares To Anchor Investors
ProceedsFromIssuanceOfOrdinarySharesToAnchorInvestors
0
ivcp Proceeds From Issuance Of Ordinary Shares To Anchor Investors
ProceedsFromIssuanceOfOrdinarySharesToAnchorInvestors
6750
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
656623
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25250000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
203975127
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-413917
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
875831
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
875831
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
461914
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
875831
ivcp Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
320185
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2442494
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
36958138
CY2022 ivcp Initial Accretion From Overallotment Warrants
InitialAccretionFromOverallotmentWarrants
2806250
ivcp Initial Accretion From Overallotment Warrants
InitialAccretionFromOverallotmentWarrants
0
CY2022 ivcp Deferred Underwriting Fee Incurred But Not Yet Paid
DeferredUnderwritingFeeIncurredButNotYetPaid
875000
ivcp Deferred Underwriting Fee Incurred But Not Yet Paid
DeferredUnderwritingFeeIncurredButNotYetPaid
7000000
CY2022 ivcp Forfeiture Of Ordinary Shares By Sponsor
ForfeitureOfOrdinarySharesBySponsor
13
ivcp Forfeiture Of Ordinary Shares By Sponsor
ForfeitureOfOrdinarySharesBySponsor
225
CY2021Q4 ivcp Term Of Restricted Investments
TermOfRestrictedInvestments
P185D
CY2022Q4 ivcp Number Of Operating Businesses Included In Initial Business Combination
NumberOfOperatingBusinessesIncludedInInitialBusinessCombination
1
CY2022Q4 ivcp Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.1
CY2022Q4 us-gaap Minimum Net Worth Required For Compliance
MinimumNetWorthRequiredForCompliance
5000001
CY2022Q4 ivcp Percentage Of Public Shares That Can Be Redeemed Without Prior Consent
PercentageOfPublicSharesThatCanBeRedeemedWithoutPriorConsent
0.15
CY2022Q4 ivcp Percentage Of Public Shares That Would Not Be Redeemed If Business Combination Is Not Completed With In Initial Combination Period
PercentageOfPublicSharesThatWouldNotBeRedeemedIfBusinessCombinationIsNotCompletedWithInInitialCombinationPeriod
1
CY2022 ivcp Period To Complete Business Combination From Closing Of Initial Public Offering
PeriodToCompleteBusinessCombinationFromClosingOfInitialPublicOffering
P18D
CY2022 ivcp Period To Complete Business Combination From Closing Of Initial Public Offering
PeriodToCompleteBusinessCombinationFromClosingOfInitialPublicOffering
P18D
CY2022Q4 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000
CY2021Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.1
CY2022Q4 ivcp Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.1
CY2022Q4 us-gaap Cash
Cash
461914
CY2022Q4 ivcp Working Capital Surplus
WorkingCapitalSurplus
63250
CY2022Q3 ivcp Percentage Of Excise Tax On Repurchases Of Stock
PercentageOfExciseTaxOnRepurchasesOfStock
0.01
CY2022Q3 ivcp Percentageofamountofexcisetaxisequaltoamountoffairmarketvalueofthesharesrepurchased
Percentageofamountofexcisetaxisequaltoamountoffairmarketvalueofthesharesrepurchased
0.01
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div>
CY2022Q4 us-gaap Cash
Cash
461914
CY2021Q4 us-gaap Cash
Cash
875831
CY2022Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
229792494
CY2021Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
202000481
CY2022Q4 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20600000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Depository Insurance Coverage</div> of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q4 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3000000
CY2021Q4 ivcp Cash Deposited In To Operating Bank Account
CashDepositedInToOperatingBankAccount
2600000
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2284
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2284
CY2021Q4 ivcp Loansfromworkingcapital
Loansfromworkingcapital
0
CY2022Q4 ivcp Loansfromworkingcapital
Loansfromworkingcapital
0
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0

Files In Submission

Name View Source Status
0001193125-23-110542-index-headers.html Edgar Link pending
0001193125-23-110542-index.html Edgar Link pending
0001193125-23-110542.txt Edgar Link pending
0001193125-23-110542-xbrl.zip Edgar Link pending
d484779d10k.htm Edgar Link pending
d484779dex21.htm Edgar Link pending
d484779dex311.htm Edgar Link pending
d484779dex312.htm Edgar Link pending
d484779dex321.htm Edgar Link pending
d484779dex322.htm Edgar Link pending
d484779dex45.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ivcp-20221231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ivcp-20221231_def.xml Edgar Link unprocessable
ivcp-20221231_lab.xml Edgar Link unprocessable
ivcp-20221231_pre.xml Edgar Link unprocessable
d484779d10k_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ivcp-20221231_cal.xml Edgar Link unprocessable